NCT06063538RecruitingEarly phase 1
Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone
A Prospective Study Using Intra-Pericardial Amiodarone for the Prevention of Postoperative Atrial Fibrillation (POAF) in Patients Undergoing Cardiac Arterial Bypass Grafting and/or Valve Surgery
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the combination of CardiaMend, with the addition of amiodarone in the prevention of postoperative atrial fibrillation (POAF) in patients undergoing cardiac arterial bypass grafting (CABG) or valve surgery.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 63 (estimated)
- First submitted
- 21 Sept 2023
- Start date
- 15 Feb 2024
- Primary completion date
- Jun 2027
- Lead sponsor
- University of Chicago
- Diseases
- Atrial fibrillation
- NCT number
- NCT06063538
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 63
- From 15 Feb 2024 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant oral or IV systemic corticosteroid therapy and/or other constant anti-inflammatory therapies.
- Patients already receiving amiodarone as a treatment for atrial fibrillation or ventricular arrhythmias.
- Disease of the left pleura, previous intervention in the left pleural space, or chest deformity.
Other illness
- Any condition which could interfere with the subject's ability to comply with the study.
- Active skin or deep infection at the site of implantation.
- History of chronic wounds or wound-healing disorders.
- Known connective tissue diseases (e.g. Ehlers-Danlos syndrome, Epidermolysis bullosa, Marfan syndrome, Osteogenesis imperfecta).
- Immune-suppressed subjects, immune-deficiency subjects (properly managed diabetes mellitus is not an exclusion criterion).
- Subjects with end-stage chronic-renal disease / dialysis.
Other
- Subject unable to give voluntary written informed consent, is unlikely to cooperate or is legally incompetent, including subjects who are institutionalized by court or official order, or in a dependency relationship with, testing center or investigator.
- Ongoing participation in an interventional clinical study or during the preceding 30 days.
- Female subjects who are pregnant, breastfeeding, were pregnant within the last three months, or are planning to become pregnant during the course of the study.
- STS (Society of Thoracic Surgeons Score) risk score \>5.5% for 30 day mortality.
Who the study is looking for
- Subject aged 20-85 years old.
- Patients able to provide written informed consent, understand, and be willing to comply with study-related procedures.
- Participants who are scheduled to undergo open-chest cardiac surgery via complete median sternotomy. Includes:
- Coronary artery bypass graft (CABG) and/or valve repair/replacement procedures (aortic, mitral, or tricuspid)
- Isolated ascending aortic aneurysm replacement/repair
- Note: Left atrial appendage (LAA) procedures are allowed if CABG and/or valve repair or replacement is the qualifying surgical procedure, but is not a qualifying surgical procedure on its own.
- In sinus rhythm at the time of office visit and prior electrocardiogram (EKG) (note: continuous EKG monitoring for 48 hours is not required).
Age in the registry: 20 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University Of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.